FindTrial
Sign In

A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Inhaled Versus Intravenous Pentamidine in Pneumocystis Carinii Pneumonia in the Acquired Immunodeficiency Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002292
Enrollment
Unknown
Registered
2001-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Pneumonia, Pneumocystis Carinii

Keywords

AIDS-Related Opportunistic Infections, Pneumonia, Pneumocystis carinii, Pentamidine, Injections, Intravenous, Administration, Inhalation, Aerosols, Acquired Immunodeficiency Syndrome

Brief summary

To compare parenteral versus inhaled pentamidine in patients with documented Pneumocystis carinii pneumonia (PCP) with AIDS.

Interventions

DRUGPentamidine isethionate

Sponsors

LyphoMed
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Exclusion criteria

Co-existing Condition: Patients with the following are excluded: * Previous history of adverse reaction to pentamidine. * History of asthma. * Pulmonary Kaposi's sarcoma. Patients with the following are excluded: * Previous history of adverse reaction to pentamidine. * History of asthma. * Pulmonary Kaposi's sarcoma. * Inability to understand the consent procedure. All patients hospitalized at Cedars-Sinai Medical Center with AIDS and possible Pneumocystis carinii pneumonia (PCP) will be eligible. * Patients with HIV antibody or AIDS and a clinical presentation suggesting PCP are eligible.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026